Literature DB >> 33442064

Aducanumab and the FDA - where are we now?

Howard Fillit1, Allan Green2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33442064     DOI： 10.1038/s41582-020-00454-9

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  20 in total

1.  Distal radius fractures and risk of incident neurocognitive disorders in older adults: a retrospective cohort study.

Authors:  Joshua M Baruth; Maria I Lapid; Bart Clarke; Alexander Y Shin; Elizabeth J Atkinson; Jonas Eberhard; Guido Zavatta; Jörgen Åstrand
Journal:  Osteoporos Int       Date:  2022-07-15       Impact factor: 5.071

Review 2.  Aduhelm, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer's Disease: A comprehensive review.

Authors:  Hannah W Haddad; Garett W Malone; Nicholas J Comardelle; Arielle E Degueure; Salomon Poliwoda; Rachel J Kaye; Kevin S Murnane; Adam M Kaye; Alan D Kaye
Journal:  Health Psychol Res       Date:  2022-07-28

3.  Aducanumab, a Novel Anti-Amyloid Monoclonal Antibody, for the Treatment of Alzheimer's Disease: A Comprehensive Review.

Authors:  Hannah W Haddad; Garett W Malone; Nicholas J Comardelle; Arielle E Degueure; Adam M Kaye; Alan D Kaye
Journal:  Health Psychol Res       Date:  2022-01-30

4.  Therapeutic effects of anti-amyloid β antibody after intravenous injection and efficient nose-to-brain delivery in Alzheimer's disease mouse model.

Authors:  Noriyasu Kamei; Ayaka Hashimoto; Erina Tanaka; Kaho Murata; Maika Yamaguchi; Natsuki Yokoyama; Masahiro Kato; Keisuke Oki; Takashi Saito; Takaomi C Saido; Mariko Takeda-Morishita
Journal:  Drug Deliv Transl Res       Date:  2022-01-11       Impact factor: 5.671

Review 5.  A2A Adenosine Receptor Antagonists in Neurodegenerative Diseases.

Authors:  Stefania Merighi; Pier A Borea; Katia Varani; Fabrizio Vincenzi; Kenneth A Jacobson; Stefania Gessi
Journal:  Curr Med Chem       Date:  2022       Impact factor: 4.740

Review 6.  Brain-derived neurotrophic factor in Alzheimer's disease and its pharmaceutical potential.

Authors:  Lina Gao; Yun Zhang; Keenan Sterling; Weihong Song
Journal:  Transl Neurodegener       Date:  2022-01-28       Impact factor: 8.014

7.  The Beneficial Effects of Combining Anti-Aβ Antibody NP106 and Curcumin Analog TML-6 on the Treatment of Alzheimer's Disease in APP/PS1 Mice.

Authors:  Ih-Jen Su; Chia-Yu Hsu; Santai Shen; Po-Kuan Chao; John Tsu-An Hsu; Jung-Tsung Hsueh; Jia-Jun Liang; Ying-Ting Hsu; Feng-Shiun Shie
Journal:  Int J Mol Sci       Date:  2022-01-05       Impact factor: 5.923

Review 8.  The promise of microRNA-based therapies in Alzheimer's disease: challenges and perspectives.

Authors:  Hannah Walgrave; Lujia Zhou; Bart De Strooper; Evgenia Salta
Journal:  Mol Neurodegener       Date:  2021-11-06       Impact factor: 14.195

9.  Targeting MicroRNA-485-3p Blocks Alzheimer's Disease Progression.

Authors:  Han Seok Koh; SangJoon Lee; Hyo Jin Lee; Jae-Woong Min; Takeshi Iwatsubo; Charlotte E Teunissen; Hyun-Jeong Cho; Jin-Hyeob Ryu
Journal:  Int J Mol Sci       Date:  2021-12-04       Impact factor: 5.923

Review 10.  Critical Appraisal of Amyloid Lowering Agents in AD.

Authors:  Boris Decourt; Fadel Boumelhem; Evans D Pope; Jiong Shi; Zoltan Mari; Marwan Noel Sabbagh
Journal:  Curr Neurol Neurosci Rep       Date:  2021-06-10       Impact factor: 6.030
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.